Connect with us

Cannabis

Leviathan Natural Products Increases Value of Debt Facility

Newsfile

Published

on

Toronto, Ontario–(Newsfile Corp. – July 30, 2020) – Leviathan Natural Products Inc. (CSE: EPIC) (the “Company” or “Leviathan“) announces that effective July 24, 2020, it increased the value of a debt facility with a major shareholder from $5.0 million to $5.5 million at the same terms and conditions as the original agreement.

The terms of the original agreement were initially disclosed in the Company’s news release dated October 31, 2019. The loan will have a maturity date of 15 October, 2021, with the outstanding portion of the principal amount bearing interest at a rate of ten percent (10%) per annum from the date of each advance, payable three times per year: 30 April, 31 August, and 31 December. Leviathan may, at its discretion, repay the balance of principal and/or interest owing at any time without penalty. This financing is meant to be non-dilutive. The Company will primarily use the funding to advance its operations and allow time to complete the refinancing of the building and equipment at its facility in Carthage, Tennessee.

About Leviathan Natural Products

Leviathan Natural Products concentrates on non-psychoactive hemp derived products for the health and wellness market. Leviathan plans on executing a series of buy and build transactions extending across all vertical markets in Canada and internationally. The Company’s global capabilities position it to become a leading multi-jurisdictional cannabinoid producer – one that brings together the best cannabinoid products, brands and expertise from Canada and around the world. The Leviathan portfolio currently comprises Jekyll+Hyde Brand Builders Inc., a marketing services agency specializing in the cannabis/hemp sector; Leviathan US Inc., which intends to begin manufacturing cannabidiol products in August 2020 from its facility in Carthage, Tennessee; LCG Holdings Inc., a hemp cultivation and processing facility in Carmen de Viboral, Colombia, which expects to be operational in calendar Q1 2021; and Woodstock Biomed Inc., which owns a 30-acre property with greenhouse infrastructure in Pelham, Ontario. Development at Woodstock is temporarily suspended pending the adoption of new municipal regulations and zoning by-law amendments imposed by the Town of Pelham that may restrict cannabis and hemp operations.

www.Leviathan-Naturals.com

For more information, contact Martin J. Doane, CEO, Leviathan Natural Products Inc. at 416.903.6691 or Jayne Beckwith, Chief Communications Officer, Leviathan Natural Products Inc. at 416.806.0591.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

# # #

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or negatives of these terms and similar expressions. Forward-looking statements are based on certain assumptions, including that renovations at the Carthage, Tennessee facility will be completed sufficiently quickly, the Company being able to secure sufficient hemp biomass to enable commercial production at the Carthage, Tennessee facility, pre-construction and construction activities will be completed at the Carmen de Viboral, Colombia facility by Q1/2021, the Company will obtain equipment financing for construction activities and the purchase of extraction equipment at the Carmen de Viboral facility, and that the Town of Pelham, Ontario and the newly introduced zoning by-law and other related amendments will not unduly restrict the Company’s cannabis and hemp operations. Other assumptions include the successful application to be a licensed cannabis producer and seller, expected revenue will not be less than necessary to fund growth opportunities and the financing of the construction of the greenhouses, results and profits from operations will not be less than required to fund growth opportunities and construction of greenhouses, performance, industry trends, growth opportunities will be available, and general business, economic, competitive, political and social uncertainties will not prevent the Company from conducting its business. While Leviathan considers these assumptions to be reasonable based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Forward‐ looking information speaks only to such assumptions as of the date of this release.

Forward-looking statements also necessarily involve known and unknown risks, including without limitation, risks associated with general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, the inability to access sufficient capital on favourable terms, the medical and recreational cannabis industry in Canada and internationally, income tax and regulatory matters, the ability of Leviathan to execute its business strategies, competition, crop failure, currency and interest rate fluctuations, time delays to complete renovations at Carthage, Tennessee facility, the inability to secure sufficient hemp biomass to enable commercial production at the Carthage, Tennessee facility, delays in construction of the Carmen de Viboral, Colombia facility, the inability to obtain equipment financing for the Carmen de Viboral facility, the risk that the newly introduced zoning by-law and other related amendments will unduly restrict the Company’s cannabis and hemp operations in the Town of Pelham, Ontario and other risks. Readers are cautioned that the foregoing is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ from those anticipated. Forward-looking statements are not guarantees of future performance. The purpose of forward‐looking information is to provide the reader with a description of management’s expectations, and such forward‐looking information may not be appropriate for any other purpose.

Except as required by law, Leviathan disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement.

Source: Leviathan Natural Products Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60869

Cannabis

Benchmark Provides Update on Financial Condition of Potanicals

Newsfile

Published

on

Vancouver, British Columbia–(Newsfile Corp. – October 23, 2020) – Benchmark Botanics, Inc. (CSE: BBT) (“Benchmark” or the “Company”) Benchmark announces that the ongoing working capital deficiency of Potanicals Green Growers Inc. (“Potanicals“), the Company’s wholly owned subsidiary, may result in Potanicals being unable to meet all of its accounts payable at October 31, 2020, including its October 31, 2020 payroll obligations for all 39 of Potanicals’ employees, which will cause material uncertainty about Potanicals’ ability to continue as a going concern. During the period from January 1, 2019 to December 31, 2019, Potanicals had a net loss of approximately $1,736,000. As at October 22, 2020, Potanicals had cash of $102,493, and a working capital deficiency of $134,605.

The Company is actively exploring various options to address the financial difficulty issues of Potanicals, including increasing its sales from inventory, cutting its costs, restructuring its operations, and undertaking an equity or debt financing. To meet such funding requirements, if the Company closes an additional equity financing, it would be dilutive to existing shareholders. Debt financing, if available, may also involve restrictions on financing and operating activities. There is no assurance that such additional financing will be available on terms acceptable to the Company or at all. If the Company is unable to obtain additional financing as needed, it may be required to reduce the scope of the operations of Potanicals or any planned expansion. No assurances can be given that the Company will be able to raise the additional funding that may be required for such activities. The Company will provide further updates on this matter as it develops.

About Benchmark

Benchmark is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical and recreational markets in Canada. The Company’s business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp throughout Asia, in countries where it is legal to do so.

Benchmark is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint.

Benchmark’s 100% owned subsidiary, Potanicals Green Growers Inc. (“Potanicals) is a Health Canada licensed producer under the Cannabis Act and its regulations. The Company is producing at its indoor Peachland, BC Cannabis Complex and is constructing a Phase II expansion of an additional 10,000 square foot extraction facility there. Along with cultivation and production, the company’s Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetic improvements.

As part of its expansion strategy, the company and a joint venture partner completed a second facility, a 4-acre Greenhouse Operation in Pitt Meadows, BC. The Company, through Potanicals, has received its second cultivation license, effective November 29, 2019, from Health Canada for the Pitt Meadow greenhouse.

For further information, please visit the Company’s website at www.benchmarkbotanics.com or the Company’s profile at www.sedar.com.

If you would like to be added to Benchmark’s news distribution list, please sign up at Investor Relations info@bbtinc.ca.

ON BEHALF OF THE BOARD OF

BENCHMARK BOTANICS INC.
“William Ying”

William Ying
Chief Executive Officer

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements

This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66763

Continue Reading

Cannabis

PURA Addresses Next Steps to Issue Dividend of PAOG Stock

Newsfile

Published

on

Dallas, Texas–(Newsfile Corp. – October 23, 2020) – Puration, Inc. (OTC Pink: PURA) today announced that PURA management and PAO Group, Inc. (OTC Pink: PAOG) management have scheduled combined efforts next week to complete the joint documentation and submission requirements necessary to execute the planned dividend of PAOG stock to PURA shareholders. A joint PURA and PAOG announcement is scheduled for next Friday, October 30, 2020. The dividend update announcement comes today in conjunction with the overall corporate update scheduled for release today and included in its entirety below:

Corporate Update

Last month, PURA introduced Farmersville Brands and announced a major juncture in the company’s growth and development as the company pivots from its hemp derived CBD beverage industry foundation to launch a Texas flavored, holistic lifestyle branded approach into a broader, but still niche, $20 billion sector within an overall market worth at least $2 trillion.

January of this year, PURA launched an acquisition campaign as a forerunner initiative to the Farmersville Brands transition.

Since launching the acquisition campaign in January, the company has acquired a CBD confections business, a CBD pet products business and CBD sun care business. Combined with its existing beverage industry product line, PURA’s combined horizontal market opportunity ranges across over $2 trillion in market value:

Sexual wellness $39 Billion Projected Market Value

Confections $232 Billion Projected Market Value

Pet Products $202 Billion Projected Market Value

Sun Care $12.6 Billion Projected Market Value

Non-Alcoholic Beverage $1.6 Trillion Projected Market Value

Central to the Farmersville Brands transition is the construction of a lifestyle brand that embodies the values, interests, attitudes, and opinions of the population where CBD and hemp products are an ideal fit.

Farmersville Brands holistic lifestyle approach will include a certain Texas personality component built on a targeted 72-acre property in Farmersville, Texas, just north of Dallas, expected to soon be acquired by PURA.

The location is intended to be a hemp mecca were visitors can participate in and learn about the reintroduction of hemp into the American market. Visitors can engage on a recreational weekend sojourn, or engage in a professional capacity to explore the best agricultural and processing practices, and new innovative methods for utilizing hemp to construct homes or to power cars.

Earlier this week, on Wednesday, PURA announced executing a contract to purchase the 72-acre farmland parcel located in Farmersville, TX, for a consideration of $1.3 million. This is a key step in the Farmersville Brand strategy transition.

PURA also has a planned $100 million investment strategy developing to fund the Farmersville transition. The company is keeping details under wraps at the moment but anticipates making the plan pubic before year end.

PAOG Dividend Next Steps

PAO Group, inc. (OTC Pink: PAOG) recently acquired a hemp cultivation business from PURA. PAOG is building a partnership with PURA in conjunction with PAOG’s new hemp cultivation business. PAOG has announced working with PURA’s new hemp processing facility in Farmersville, Texas where the two companies will partner on the construction of a greenhouse for cultivating pharmaceutical grade hemp and a lab for CBD extraction.

PAOG’s partnership includes making PURA shareholders, shareholders of PAOG. PAOG’s purchase of PURA included a PAOG stock issued to PURA shareholders in a dividend distribution. The timing of the execution of the dividend has been impacted by PAOG’s overall large volume of work surrounding the integration of its recently acquired RespRx CBD treatment for Chronic Obstructive Pulmonary Disease (COPD) and its newly acquired hemp cultivation operations. PAOG and PURA management have committed time together next week to get the dividend process over the speed bump. A joint progress announcement is planned for a week from today, next Friday, October 30, 2020.

For more information on Puration, visit http://www.purationinc.com

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66751

Continue Reading

Cannabis

PAOG Signs Clinical Research Organization (CRO) to Advance Respiratory Cannabis Treatment Through Regulatory Approval

Newsfile

Published

on

Sandusky, Ohio–(Newsfile Corp. – October 23, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today announced executing a master services agreement with a clinical research organization in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG signed the agreement yesterday, prior to the comprehensive corporate update scheduled for publication today and included in its entirety below.

Corporate Update

Less than 90 days ago, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY) and began to transform the company into a cannabis biopharmaceutical development operation. The company has come a long way very quickly and management believes the rapid progress has been possible based on the merits of the research backing RespRx.

RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled, “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT”.

In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated affecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.

The CRO agreement signed yesterday is a year long agreement and a major step forward to advancing RespRx through the regulatory approval process. PAOG plans to make a joint announcement next week with the CRO company.

As previously announced, and in addition to the CRO agreement announced today, PAOG continues to develop pharmaceutical research and development relationships in Puerto Rico’s burgeoning, recently reinvigorated pharmaceutical industry. An announcement of an anticipated key contract in Puerto Rico is expected soon.

Part of PAOG’s pharmaceutical development strategy includes the development of a proprietary hemp cultivar. In addition to acquiring RespRx from KALY, PAOG recently acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA). PAOG is building a partnership with PURA in conjunction with PAOG’s new hemp cultivation business. PAOG has announced working with PURA’s new hemp processing facility in Farmersville, Texas where the two companies will partner on the construction of a greenhouse for cultivating pharmaceutical grade hemp and a lab for CBD extraction.

PAOG’s partnership includes making PURA shareholders, shareholders of PAOG. PAOG’s purchase of PURA included a PAOG stock issued to PURA shareholders in a dividend distribution. The timing of the execution of the dividend has been impacted by the overall large volume of work surrounding the integration of the RespRx and hemp cultivation operations and the prioritization of establishing a CRO contract. PAOG and PURA management have committed time together next week to get the dividend process over the speed bump. A joint progress announcement is planned for a week from today, next Friday, October 30, 2020.

www.paogroupinc.com

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION:

Jim DiPrima
888-272-6472
info@pao.group

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66743

Continue Reading

Trending Online

Grassnews is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Grassnews digests / hand picks the latest news about the CBD / Legal Cannabis industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Grassnews .com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania